Skip to search boxSkip to navigationSkip to main content

Flavonoids effects against bacteria associated to periodontal disease and dental caries: a scoping review

  • Bruna Tavares Carneiro
    ,
  • Fernanda Novais Arantes Maciel de Castro
    ,
  • Francine Benetti
    ,
  • ,
  • Thais Yumi Umeda Suzuki
    ,
  • Carolina Bosso André
  • Universidade Federal de Minas Gerais
    ,
  • Universidad de Los Andes
Research Output:
Contribution to journal
Review article
Peer-review

Publication Information

Output type

Research Output:
Contribution to journal
Review article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 99-113 (15 pages)

Journal (Volume, Issue Number)

Biofouling (Volume 40, Issue 2)

Publication milestones

  • Accepted/In press - 2024
  • Published - 2024

Publication status

Published - 2024

ISSN

0892-7014

Publication IDs

  • Scopus: 85186455822

Abstract

This scoping review focused on exploring the efficacy of flavonoids against bacteria associated with dental caries and periodontal diseases. Inclusion criteria comprise studies investigating the antibacterial effects of flavonoids against bacteria linked to caries or periodontal diseases, both pure or diluted in vehicle forms. The search, conducted in August 2023, in databases including PubMed/MEDLINE, Scopus, Web of Science, Embase, LILACS, and Gray Literature. Out of the initial 1125 studies, 79 met the inclusion criteria, majority in vitro studies. Prominent flavonoids tested included epigallocatechin-gallate, apigenin, quercetin, and myricetin. Predominant findings consistently pointed to bacteriostatic, bactericidal, and antibiofilm activities. The study primarily investigated bacteria associated with dental caries, followed by periodontopathogens. A higher number of publications presented positive antibacterial results against Streptococcus mutans in comparison to Porphyromonas gingivalis. These encouraging findings underline the potential applicability of commercially available flavonoids in materials or therapies, underscoring the need for further exploration in this field.

Funding Details

This study was financed in part by FAPEMIG (APQ-01185-21), CNPq (422588/2021-0). The funding sources were not involved in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
FundersFunding numbers
CNPq
422588/2021-0
FAPEMIG
APQ-01185-21